

- Maxwell KN, Soccio RE, Duncan EM, Sehayek E, Breslow JL (2003) Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. *J Lipid Res* 44(11):2109-2119
- Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. *Proc Natl Acad Sci USA* 100:928-933
- Shioji K, Kokubo Y, Mannami T, Inamoto N, Morisaki H, Mino Y, Tago N, Yasui N, Iwai N (2004) Association between hypertension and the α -adducin, β 1-adrenoreceptor and G-protein β 3 subunit genes in the Japanese population; The Suita Study. *Hypertens Res* (in press)
- Takagi S, Iwai N, Yamauchi R, Kojima S, Yasuno S, Baba T, Terashima M, Tsutsumi Y, Suzuki S, Morii I, Hanai S, Ono K, Baba S, Tomoike H, Kawamura A, Miyazaki S, Nonogi H, Goto Y (2002) Aldehyde dehydrogenase 2 gene is a risk factor for myocardial infarction in Japanese men. *Hypertens Res* 25:677-681

Keisuke Shioji · Junko Nishioka · Hiroaki Naraba
Yoshihiro Kokubo · Toshifumi Mannami
Nozomu Inamoto · Kei Kamide · Shin Takiuchi
Masayoshi Yoshii · Yoshikazu Miwa · Yuhei Kawano
Toshiyuki Miyata · Shunichi Miyazaki · Yoichi Goto
Hiroshi Nonogi · Naomi Tago · Naoharu Iwai

A promoter variant of the ATP-binding cassette transporter A1 gene alters the HDL cholesterol level in the general Japanese population

Received: 21 November 2003 / Accepted: 24 December 2003 / Published online: 21 February 2004
© The Japan Society of Human Genetics and Springer-Verlag 2004

Abstract To investigate the effects of polymorphisms in the ATP-binding cassette transporter A1 (*ABCA1*) gene on the high-density lipoprotein cholesterol (HDL-C) level and the incidence of myocardial infarction (MI), we performed association studies. Sequence analysis identified 14 polymorphisms in the promoter region of *ABCA1*. After considering linkage disequilibrium, three polymorphisms in the promoter region and 11 polymorphisms from the JSNP database were determined in 1,880 subjects recruited from the Suita Study, representing the general population in Japan. We evaluated the association between the *ABCA1* genotype and HDL-C level adjusted not only for standard factors, but also for genetic factors including *ApoA1* and *ApoE* genotypes. Of the 14 polymorphisms tested, the *G(-273)C* ($P=0.0074$), *C(-297)T* ($P=0.0195$), and *IMS-JST071749* ($P=0.0093$) polymorphisms were significantly associated with the HDL-C level in the Suita population. We could reconfirm that the

G(-273)C genotype was influential in another set of subjects ($P=0.0310$, $n=743$). However, the distribution of the *ABCA1 G(-273)C* genotype in subjects with MI ($n=598$) was not different from that in the control population ($n=801$). These results indicate that *ABCA1 G(-273)C* has a significant effect on the HDL-C level in the general Japanese population, but not on the incidence of MI.

Keywords *ABCA1* · Polymorphism · Association study · HDL cholesterol · Myocardial infarction

Introduction

The high-density lipoprotein cholesterol (HDL-C) level is inversely correlated with the development of atherosclerosis and is inversely related to the incidence of coronary artery disease (Castelli et al. 1986) and ischemic stroke in the elderly (Sacco et al. 2001). The HDL-C level has been shown to be affected by both genetic and environmental factors, including obesity, smoking, and alcohol consumption. Among genetic factors, the apolipoprotein A1 (*ApoA1*) (Groenendijk et al. 2001a,b) and *ApoE* genotypes (Lefevre et al. 1997; Katsuya et al. 2002) are well known to influence the HDL-C level.

Genetic mutations in the ATP-binding cassette transporter A1 (*ABCA1*) gene have been shown to cause Tangier disease (TD) (Bodzioch et al. 1999; Brooks-Wilson et al. 1999; Rust et al. 1999) and familial HDL deficiency (Marcil et al. 1999). *ABCA1* regulates cellular cholesterol efflux and facilitates lipid binding to *ApoA1* (Wang and Tall 2003). Patients with TD show characteristic HDL deficiency, defective apolipoprotein-mediated phospholipid and cholesterol efflux from cells, and the accumulation of macrophage foam cells in various tissues, including arteries (Clifton-Bligh et al. 1972). Recent epidemiological studies have reported that *ABCA1* polymorphisms were associated with the HDL-C level

K. Shioji · J. Nishioka · H. Naraba · N. Tago · N. Iwai (✉)
Department of Epidemiology, Research Institute,
National Cardiovascular Center,
5-7-1 Fujishirodai, Suita,
Osaka 565-8565, Japan
E-mail: niwai@res.ncvc.go.jp
Tel.: +81-6-68335012
Fax: +81-6-68352088

Y. Kokubo · T. Mannami · N. Inamoto · T. Miyata
Department of Preventive Cardiology,
National Cardiovascular Center,
5-7-1 Fujishirodai, Suita,
Osaka 565-8565, Japan

K. Kamide · S. Takiuchi · M. Yoshii · Y. Miwa · Y. Kawano
Division of Hypertension and Nephrology,
National Cardiovascular Center,
5-7-1 Fujishirodai, Suita,
Osaka 565-8565, Japan

S. Miyazaki · Y. Goto · H. Nonogi
Division of Cardiology,
National Cardiovascular Center, 5-7-1 Fujishirodai,
Suita, Osaka 565-8565, Japan

-1600	AAGGGCCATGCCACCAGA	GTTATGAGTACCTGGGACTC	CAGAATTCCTTGCCCTGGTGG	CCTCCACATGCACCTCCAGG	GCCTGCTGGGCTCTTCTTA
-1500	TGGTCTGTCTGAGTGTGG G(-1498)C	ATAGAACCACATGATGTGAGT	ACCTGGGCTTGAGCCCTGGC	CTGGAGATCCTTTGACTGT T(-1423)C	AGCATGGAGGGGGCTGTGTC
-1400	AGCTGAATGTCTGTATGACG T(-1387)C	GTGGTGGGAGTCTTGGAAATA	TGATGGAGCTGGAGTGGGA	AGAGAAGTAGGCTTGGGGCA	GCTCTCTCATGCCACCTCAT
-1300	TCTGGCCAAAACCTCAGGTCA	AACGTGAAGAGTCTAAATG	TGAATCTGCCCTTCAAGGTG	GCTACAAAAGTATCTTTGTC	AAAGTAGGAGACCTTGTGGC
-1200	CTCCACGTGCACCTCCAGGG	CCTGCTTGGGCTCTTCTAC	GGTCTGTCTGAGTCTTCT	ATGAATCTGCCCTTCAGGGC	AGATTCATATTTAGACTCTT
-1100	CACAOTTTGACCTGAGTTTT	GGCCAGAAATAAGGTGACATT	TAOTTTTGTGCTTGTATGGA	TGACTTAAATATTTAGACAT	ATGOTGTGTAGGCTGCATT AT(-1019)C
-1000	CCTACTCTTCCCTCTCTCTCT (-980)T(10)T(9)T(8)	TGCCCTCCAGTGTTTTGGG	TAOTTTTGTCTCCCTACAGC	CAAAGGCAACAGATAAGTT G(-926)T	GGAGGCTCTGGAGTGGCTACA
-900	TAATTTTACACGACTGCAAT	TCTCTGGCTGCACCTTACAA	ATGTATACAACTAAATACA	AGTCTGTGTTTTTATCACA	GGGAGGCTGATCAATATAAT
-800	GAAATTAAGAGGGGCTGTG G(-790)A	CCATATTTGTTCTGTGTTTT	GTITGTTT_GTTTCTTTTTT GTTTTGTTT(-752)C (IV #1)	GTTTTTGGCCCTCCTTCT	CTCAATTTATGAAGAGAAGC
-700	AGTAAGATGTTCTCTCTCGG	TCCTCTGAGGGACCTGGGGA	GCTCAGGCTGGGAACTCCA	AGCCAGTAGTCTGCTATCA	AAAATCAAAGTCCAGGTTG
-600	TGGGGGAAAACAAAGCAG	CCCATTACCAGAGGACTGT	CCGCCTTCCCTCACCCAG C(-559)T	CCTAGGCCTTTGAAAGGAAA	CAAAGACAAAGCAAAATGA
-500	TTGGCTCTGAGGAGATT	CAGCTTAGAGCTCTCTCTCC	CCCAATCCCTCCCTCCGGT	GAAGAACTAAGCAAGGAAA	AAAAATTCGGAAAGCAGG G(-402)C
-400	ATTTAGAGAAACAAATTC	ACTGTGCTCCCTGGCTGCG	GGAACTGTGACTAGAGATC	TGCGGCGAGCCCGAGCCC	AGCGCTTCCCGCGCTCTTA
-300	GGCCGGCGGGCCCGGGCGG C(-297)T	GGAAAGGAGCCGAGACCGCG G(-273)C	GACCCTAAGACACCTGCTGT	ACCTTCCACCCCA_CCCAC TGCGG(-226)C (IV #2)	GCACCTCCCCCAACTCCCT
-200	AGATGTGTCTGGGCGGCTG	AACGTGCGCCCTTTAAGGG	CGGCCCCCGCTCCACGTGC	TTTCTGCTGAGTACTAAAC	TACATAAACAGAGCCGGGA
-100	ACGGGGCGGGAGGAGGGAG G(-99)C	AGCACAGGCTTTGACCGATA	GTAACTCTGCGCTCGGTGC	AGCCGAATCTATAAAAGGAA	CTAGTCCGGGCAAAAACCC C(-14)T
1	GTAAATTCGAGCGAGAGTGA	GTGGGCGGGGACCCGCGA	CCCGAGCCGAC_CTTCTCTC C52A	CGGGCTCGGGCAGGGCAGG	CGGGGAGCTCCCGCACCA
101	ACAGAGCCGGTCTCAAGGC	GCTTTCTCTCTGTTTTTTC	CCCGTCTGTTTTCTCCCC	TTCTCGGAAGCTTTGTCAA	GGGTAGGAGAAAGAGACGC
201	AAACAAAAAGTGGAAAAA	GATAAGAGGCTCTCCAGTGA	CTTACTTGGCGTTATTGTT	TTGTTTCGAGGCCAAGGAGG	CTTCGGGAAGTGTCTGGTTT
301	CGGGACTTTGATCCGAGC T313C	CCCACATCCCAACCACTGC	AACTCAGATGGAGCCGGAGG	CGGTGTTAAATGGGGAGCG G38UT	ATGCTCTAGTACCGACTCTG
401	GTGACCCAGGACTCTGCGC	TGCTGCGCTTGGGCTTCC	CGACGCTGGAGACCCGGGAG	CATCTCTGGGCTGGAGACC	CGGGCCAGTACCCCGGCT

Fig. 1 Nucleotide sequence of the 5'-flanking region and exon 1 of *ABCA1*. The nucleotide sequence in *italics* indicates exon 1

(Wang et al. 2000; Clee et al. 2001; Lutucuta et al. 2001; Harada et al. 2003). However, few of these findings have been replicated, and there are inconsistencies among previous association studies. Accordingly, the associations between *ABCA1* variants and HDL-C are still controversial (Singaraja et al. 2003). One possible reason for these differences may be that the sample sizes in these studies were relatively small and lacked statistical power. Thus, to evaluate the effect of polymorphisms in *ABCA1* on the HDL-C level, we conducted an association study using a large cohort (the Suita population, $n=1,880$), representing the general population in Japan.

Materials and methods

Subjects

The Suita population The selection criteria and design of the Suita Study have been described previously (Mannami et al. 1997; Shioji et al. 2004). The genotypes were determined in 1,880 consecutive subjects who visited the National Cardiovascular Center between April 2002 and February 2003 (867 male subjects, 1,013 female subjects).

The hypertension group The hypertension (HTN) group consisted of 743 Japanese subjects (422 men and 321 women), aged 18–91 years [65.2 ± 0.4 (mean \pm SEM)], who were enrolled in the Division of Hypertension and Nephrology at the National Cardiovascular Center between May 2001 and April 2003.

The myocardial infarction group The selection criteria and design of the myocardial infarction (MI) group have been described




Fig. 2 Schema of *ABCA1* and the position of the determined polymorphisms. Grayboxes indicate exonic regions

previously (Takagi et al. 2002). This group consisted of 706 patients with MI (598 men and 108 women, aged 61.3 ± 0.4 years) who were enrolled in the Division of Cardiology at National Cardiovascular Center between May 2001 and April 2003. In the present study, we investigated only males ($n=598$).


Written informed consent was obtained from every subject after a full explanation of the study, which was approved by the Ethics Committee of the National Cardiovascular Center and by the Committee on Genetic Analysis and Genetic Therapy of the National Cardiovascular Center.

DNA studies

The regions of the promoter and exon 1 in *ABCA1* were sequenced for polymorphisms in 24 subjects (Fig. 1). The primer sequences are available on request. For exonic regions (Fig. 2), we selected nine SNPs for genotyping from the public database (JSNP, <http://snp.ims.u-tokyo.ac.jp>) (Iida et al. 2001; Hirakawa et al. 2002). Well-known common variants, *ABCA1* R219K and I823M, were also selected (Wang et al. 2000; Clee et al. 2001; Harada et al. 2003).

The preliminary study revealed that *JST-IMS005607* had the greatest effect on the HDL-C level among seven SNPs on the *ApoA1* region, including the promoter region (up to -3Kb).

Fig. 3A, B Residual HDL cholesterol levels among the *ABCA1* *G(-273)C*, *C(-297)T*, and *G(-790)A* genotypes. A Residual HDL cholesterol levels adjusted for sex, age, body-mass index, smoking, and alcohol consumption. B Residual HDL cholesterol levels adjusted for sex, age, body-mass index, smoking, alcohol consumption, *ApoE* genotype, and *ApoA1* genotype (*JST-IMS005603*)



Thus, we selected *JST-IMS005607* for adjusting HDL-C. The genotyping of *ApoE* was performed according to a previous report (Katsuya et al. 2002). *ApoE* polymorphisms were categorized into three genotypes: *E2* (*e2/e2* + *e2/e3* + *e2/e4* subjects), *E3* (*e3/e3* subjects), *E4* (*e3/e4* + *e4/e4* subjects) (Lefevre et al. 1997). All polymorphisms were determined by the TaqMan System.

Statistical analysis

Values are expressed as mean \pm standard error of the mean (SEM). For triglyceride values, a logarithmic transformation was applied for the statistical test, but untransformed values are shown in the Tables 1 and 2. All statistical analyses were performed with the JMP statistical package (SAS Institute). Values of $P < 0.05$ were considered to indicate statistical significance. Multiple linear regression and multiple logistic analyses were performed with other covariates. The residual HDL-C level was calculated by adjusting for sex, age, and body-mass index (BMI), smoking (cigarettes/day) and consumption of alcohol (ethanol, ml/week). For analyses of the effects of the *ABCA1* genotype (in the Suita population), the residual HDL-C level was calculated by adjusting not only for the above five factors, but also for the *ApoA1* (*JST-IMS005603*), and the *ApoE* (*E2*, *E3*, and *E4*) genotypes. Differences in numerical data among the groups were evaluated by one-way analysis of variance (ANOVA). Hardy-Weinberg equilibrium was calculated by a chi-square test (Table 3). To measure linkage disequilibrium (LD) between SNPs, D' and r^2 values were analyzed using the SNPalyze statistical package (Dynacom).

Results

Polymorphisms of the 5'-flanking region and exon 1 of the *ABCA1* gene

We found 14 polymorphisms in the promoter region, 1 polymorphism in exon 1 (5'-untranslated region), and 2 polymorphisms in intron 1 (Fig. 1).

LD was evaluated by calculating r^2 values (Table 1). We regarded $r^2 > 0.5$ as tight linkage. The minor allele frequency of the *T(-1423)C* and *G52A* polymorphisms was low (4% each), and these SNPs were neglected in further analyses. The frequencies of *T(10)*, *T(9)*, and *T(8)* were 4, 92, and 4%, respectively, in the *(-980)T(10)/T(9)/T(8)* polymorphism, and this polymorphism was also neglected because this is not suitable for TaqMan genotyping. Accordingly, we selected three polymorphisms, *G(-790)A*, *C(-297)T*, and *G(-273)C*, for the following association study.

Association study of *ApoA1* and *ApoE*

To observe the effect of *ABCA1* polymorphisms on the HDL-C level more clearly, the HDL-C level should be adjusted by various well-known influential factors.

The *ApoA1* *IMS-JST005603* polymorphism was associated with the levels of HDL-C and triglyceride [HDL-C: TT 1.54 ± 0.001 mmol/l, TC 1.59 ± 0.02 , CC 1.68 ± 0.04 , $P = 0.0002$ (residual); triglyceride: TT 1.26 ± 0.03 mmol/l, TC 1.15 ± 0.04 , CC 0.95 ± 0.09 , $P < 0.0001$ (residual)]. *IMS-JST005603* corresponds to the *HaeIII* (*C317T*) polymorphism described in a previous paper (Groenendijk et al. 2001b).

The *ApoE* polymorphism was also strongly associated with the levels of total cholesterol and HDL-C [total cholesterol: *E2* 5.13 ± 0.06 mmol/l, *E3* 5.37 ± 0.02 , *E4* 5.41 ± 0.05 , $P = 0.0002$ (residual); HDL-C: *E2* 1.67 ± 0.03 mmol/l, *E3* 1.56 ± 0.01 , *E4* 1.52 ± 0.02 , $P < 0.0001$ (residual)].

Accordingly, we evaluated the effect of the *ABCA1* polymorphisms on the HDL-C level adjusted for the

Table 1 Linkage disequilibrium between SNPs in the 5'-flanking region and exon 1 of the *ABCA1* gene. I/D#1 GTTTGT(−752)

Genotype	G(−1498)C	T(−1423)C	T(−1387)C	AT(−1019)(−)	G(−926)T	G(−790)A	I/D#1	C(−559)T
G(−1498)C		0.01976	0.41818***	1***	0.41818***	0.00047	0.67347***	0.22034**
T(−1423)C			0.04726	0.01976	0.04726	0.01003	0	0.06087
T(−1387)C				0.41818***	1***	0.00111	0.67347***	0.65714***
AT(−1019)(−)					0.41818***	0.00047	0.67347***	0.22034**
G(−926)T						0.00111	0.67347***	0.65714***
G(−790)A							0.14667*	0.16483**
I/D#1								1***
C(−559)T								
G(−402)C								
C(−297)T								
G(−273)C								
I/D#2								
G(−99)C								
C(−14)T								
C52A								
T313C								
G380T								

R^2 values are shown in the upper right, and bolded values indicate $r^2 > 0.5$. Absolute D' -values are shown in the lower left, and bolded significance levels: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$

ApoA1 IMS-JST005603 and *ApoE* polymorphisms in addition to standard factors, including sex, age, BMI, smoking, and consumption of alcohol.

Association study of *ABCA1* (Suita population)

The association between the G(−273)C polymorphism and the lipid level in the Suita population is presented in Table 2. The genotype frequency of the G(−273)C polymorphism in the Suita population was not deviated from the Hardy-Weinberg equilibrium. The HDL-C level adjusted for age, sex, BMI, smoking, and consumption of alcohol was significantly associated with the G(−273)C polymorphism ($P = 0.0148$). The G(−273)C polymorphism was even more tightly associated with the HDL-C level when adjusted for the *ApoE* and *ApoA1* (IMS-JST005603) genotypes in addition to the standard factors ($P = 0.0074$). The C(−297)T polymorphism was also associated with the HDL-C level ($P = 0.0455$ adjusted for age, sex, BMI, smoking, and consumption of alcohol; $P = 0.0195$ when also adjusted for the *ApoE* and *ApoA1* genotypes). The effect of the C(−297)T polymorphism on the HDL-C level may be, at least in part, explained by its linkage with the G(−273)C polymorphism ($r^2 = 0.46667$, D' value = 1, $P < 0.0001$). G(−790)A was not associated with the lipid levels. Among the polymorphisms selected from JSNPs, including R219K and I823M, only the IMS-JST071749 polymorphism was associated with the HDL-C level ($P = 0.0060$ adjusted for age, sex, BMI, smoking, and consumption of alcohol; $P = 0.0093$ when also adjusted for the *ApoE* and *ApoA1* (IMS-JST005603) genotypes). The R219K and I823M polymorphisms were not associated with the HDL-C level [$P = 0.3877$ (R219K) and $P = 0.2286$ (I823M) adjusted for age, sex, BMI, smoking and consumption of alcohol; $P = 0.1926$ (R219K) and $P = 0.1209$ (I823M) when also adjusted for the *ApoE* and *ApoA1* genotypes].

Association study of *ABCA1* (HTN group)

To reconfirm the association between the G(−273)C, C(−297)T, and IMS-JST071749 polymorphisms and the HDL-C level, we determined the genotypes in the HTN group. As shown in Table 3, the G(−273)C polymorphism was associated with the residual HDL-C level ($P = 0.0310$). The genotype frequency of the G(−273)C polymorphism in the HTN group was in accordance with Hardy-Weinberg equilibrium and did not differ from that of the Suita population ($P = 0.2953$). The C(−297)T ($P = 0.1829$) and IMS-JST071749 ($P = 0.4130$) polymorphisms were not associated with the residual HDL-C level. Thus, a positive association was observed between G(−273)C and the HDL-C level in two groups: the Suita population and the HTN group.

Association between *ABCA1* G(−273)C and incidence of MI

We next evaluated whether the *ABCA1* G(−273)C polymorphism was associated with the incidence of MI. The HDL-C level in the male MI group (1.09 ± 0.01 , $P < 0.0001$) was significantly lower than that in the male Suita subjects (1.44 ± 0.02). The effects of this genotype on the HDL-C level were not observed in this group, probably because a substantial proportion of this group had dyslipidemia and had been treated with hypolipidemic drugs.

No significant association was observed between the *ABCA1* G(−273)C polymorphism and the incidence of MI [the MI group: GG $n = 212$ (38.6%), GC $n = 289$ (45.2%), CC $n = 130$ (16.2%); the Suita population: GG $n = 309$ (35.5%), GC $n = 362$ (48.3%), CC $n = 130$ (16.2%), $P = 0.4443$].

(-), I/D#2T GGGG(-226)(-)

G(-402)C	C(-297)T	G(-273)C	I/D#2	G(-99)C	C(-14)T	C52A	T313C	G380T
0.22034**	0.73333***	0.22034**	0.73333***	0.29781***	0.55012***	0.01524	0.55012***	0.52781***
0.06087	0.01449	0.06087	0.01449	0.06636	0.10559*	0.21726***	0.10559*	0.11538*
0.65714***	0.30667***	0.65714***	0.30667***	0.71214***	0.37882***	0.04726	0.37882***	0.36111***
0.22034**	0.73333***	0.22034**	0.73333***	0.29781***	0.55012***	0.01524	0.55012***	0.52781***
0.65714***	0.30667***	0.65714***	0.30667***	0.71214***	0.37882***	0.04726	0.37882***	0.36111***
0.16483**	0.07692	0.16483**	0.07692	0.15119**	0.09502*	0.01003	0.09502*	0.09582*
1***	1***	1***	1***	0.40741***	1***	0.06158	1***	1***
1***	0.46667***	1***	0.46667***	0.46798***	0.57647***	0.06087	0.57647***	0.55981***
	0.46667***	1***	0.46667***	0.46798***	0.57647***	0.06087	0.57647***	0.55981***
		0.46667***	1***	0.21839**	0.80952***	0	0.80952***	0.7978***
			0.46667***	0.46798***	0.57647***	0.06087	0.57647***	0.55981***
				0.21839**	0.80952***	0	0.80952***	0.7978***
					0.26978***	0.06636	0.26978***	0.25325***
						0.10559*	1***	1***
							0.10559*	0.11538*
								1***

values indicate $D' > 0.5$. All values refer to the variant allele indicated in the table

Table 2 Lipid levels in the *ABCA1* G(-273)C genotypes (Suita population). Subjects who were receiving anti-hyperlipidemic medication were excluded. Values are mean \pm SEM. P-values calculated by ANOVA

Factors	GG	GC	CC	P-value
n (male/female)	306/291	358/415	127/129	
Age (y)	64.1 \pm 0.5	63.7 \pm 0.4	63.9 \pm 0.7	0.7934
BMI (kg/m ²) ^a	22.7 \pm 0.1	22.4 \pm 0.1	22.9 \pm 0.2	0.0607
Smoking (cigarettes/day)	9.2 \pm 0.5	8.5 \pm 0.5	8.6 \pm 0.8	0.5806
Alcohol consumption (ml/week)	85.7 \pm 5.5	80.1 \pm 4.9	71.3 \pm 8.5	0.3597
Total cholesterol (mmol/l)	5.31 \pm 0.03	5.36 \pm 0.03	5.38 \pm 0.05	0.3559
HDL ^b cholesterol (mmol/l)	1.53 \pm 0.02	1.58 \pm 0.01	1.60 \pm 0.03	0.0258
Triglycerides (mmol/l) ^c	1.25 \pm 0.04	1.15 \pm 0.03	1.18 \pm 0.05	0.2583
Residual HDL cholesterol (mmol/l) ^d	-0.03 \pm 0.01	0.00 \pm 0.01	0.05 \pm 0.02	0.0148
Residual HDL cholesterol (mmol/l) ^e	-0.03 \pm 0.01	0.01 \pm 0.01	0.05 \pm 0.02	0.0074

^aBody-mass index

^bHigh-density lipoprotein

^cTest performed on log-transformed values

^dResidual HDL cholesterol was adjusted for sex, age, body-mass index, smoking, and alcohol consumption

^eResidual HDL cholesterol was adjusted for sex, age, BMI, smoking, alcohol consumption, *ApoE* genotype, and *ApoA1* genotype (*JST-IMS005603*)

Table 3 Lipid levels in the *ABCA1* G(-273)C genotypes (hypertension group). Values are mean \pm SEM. P-values calculated by ANOVA

Factors	GG	GC	CC	P-value
n (male/female)	165/128	196/141	58/47	
Age (y)	64.5 \pm 0.6	65.6 \pm 0.6	65.3 \pm 1.1	0.4561
BMI (kg/m ²)	24.1 \pm 0.3	23.8 \pm 0.3	23.3 \pm 0.4	0.2766
Smoking (cigarettes/day)	11.6 \pm 0.9	10.9 \pm 0.9	12.1 \pm 1.6	0.7828
Drinking habit (I/II) ^a	117/170	154/180	41/60	0.3460
Total cholesterol (mmol/l)	5.18 \pm 0.05	5.28 \pm 0.05	5.33 \pm 0.09	0.2316
HDL cholesterol (mmol/l)	1.31 \pm 0.02	1.36 \pm 0.02	1.44 \pm 0.04	0.0259
Triglycerides (mmol/l) ^b	1.54 \pm 0.07	1.52 \pm 0.07	1.64 \pm 0.12	0.9429
Residual HDL cholesterol (mmol/l) ^c	-0.04 \pm 0.02	0.02 \pm 0.02	0.07 \pm 0.04	0.0310

^aDrinking habit: I subjects with drinking habit, II subjects without drinking habit

^bTest performed on log-transformed values

^cResidual HDL cholesterol was adjusted for sex, age, BMI, smoking, and drinking habit

Discussion

In the present study, we evaluated the effects of polymorphisms in *ABCA1* on the HDL-C level using a

large cohort representing the general population in Japan (the Suita Study). To evaluate the genetic influence of *ABCA1* polymorphisms on HDL-C level, the HDL-C level was adjusted not only for standard

factors but also for other important genetic factors including the *ApoA1* and *ApoE* polymorphisms. Moreover, we reconfirmed the effects of *ABCA1* *G(-273)C* polymorphism on HDL-C in the HTN group. We next investigated the association between the *ABCA1* *G(-273)C* and the incidence of MI, but did not observe any association.

The present study is distinguished by three main features: (1) an association study using a large cohort study (the Suita population), (2) taking into account of the influence of the *ApoA1* and *ApoE* polymorphisms, and (3) a confirmation of the association using another set of subjects (the HTN group).

We found that three SNPs were associated with the HDL-C level in 14 SNPs of the *ABCA1* gene in the Suita population. However, if we applied Bonferroni's correction for multiple tests, three SNPs might not be considered significantly associated with the HDL-C level [*G(-273)C*, $P=0.1036$; *C(-297)T*, $P=0.273$; *IMS-JST071749*, $P=0.1302$, P values are corrected by multiplying with 14 (14 SNPs)]. Thus, we verified this positive association in another set of subjects (the HTN group). This association study revealed that *G(-273)C*, but not *C(-297)T* or *IMS-JST071749*, was associated with the HDL-C level. Thus, it is highly likely that *ABCA1* *G(-273)C* was truly associated with the HDL-C level.

Since the *ABCA1* *G(-273)C* polymorphism is in the promoter region, it is likely that this polymorphism may alter the expression level of *ABCA1*. However, this polymorphic site had no consensus sequence for transcriptional factors. The *TGGGG(-226)(-)* insertion-deletion polymorphism, which is one of the polymorphisms in LD with the *G(-273)C* polymorphism ($r^2=0.46667$), was in the middle of the consensus sequence of the ZNF202 binding site (GnT repeat)(Porsch-Ozcuremez et al. 2001). The insertion allele, which mainly corresponds to the *(-273)C* allele, should disrupt this binding site and may be associated with higher transcriptional activity of the *ABCA1* gene, which may lead to higher HDL cholesterol levels. However, the *C(-297)T* polymorphism, which was in more tight LD with the *TGGGG(-226)(-)* insertion-deletion polymorphism, appeared to have less effect on the HDL cholesterol level than the *G(-273)C* polymorphism. It remains to be determined whether this discrepancy merely reflects a statistical error or if the *G(-273)C* polymorphism might have additional functional significance. A more detailed promoter analysis will be needed to determine which polymorphisms are functionally important.

The present study revealed that the *ABCA1* *I823M* polymorphism was not associated with the HDL-C level, inconsistent with a previous report (Harada et al. 2003). This discrepancy may be due to the study design, since a small-scale association study has relatively weak statistical power. In the present study, the sample power was 0.77 for the distribution, sample size, frequencies of the alleles, and α value (0.05, two-tailed).

The sample size in the previous study ($n=410$) does not seem to be sufficient to give adequate statistical power. Moreover, the frequency of the *I823* allele in the previous study (allele frequency 0.492) was different from that in the Suita population (0.36) and JSNP information (0.38). Thus, the subjects in the previous study did not seem to be representative of the general Japanese population, as noted by Harada et al. (2003).

Recently, the polymorphisms in the promoter region of *ABCA1*, which corresponds to *C(-559)T* in the present study and seems to be in tight linkage with *G(-273)C* ($r^2=1$, D' -value=1), was found to be modestly, but not significantly ($P=0.09$), associated with the HDL-C level using LCAS subjects (Lutucuta et al. 2001). The effect of the *ABCA1* *G(-273)C* polymorphism on the HDL-C level was significant, but still relatively weak ($r^2=0.0050$). Accordingly, the sample size ($n=372$) in the previous study (Lutucuta et al. 2001) seems to have been too small to detect the effect of polymorphisms on the HDL-C level clearly.

While the *ABCA1* *G(-273)C* polymorphism was associated with HDL-C level, it was not found to be associated with the incidence of MI. The *ApoE* polymorphism (*E2*, *E3*, and *E4*) had the greatest influence on the HDL-C level among the three polymorphisms, *ABCA1* *G(-273)C* ($r^2=0.0050$), *ApoA1* *JST-IMS005603* (0.0100), and *ApoE* (0.0118). However, the *ApoE* polymorphism was only weakly associated with the incidence of MI ($P=0.0840$). Thus, *ABCA1* *G(-273)C* may have too weak an influence on the HDL-C level to alter the incidence of MI through a reduction of the HDL-C level. More large numbers of MI subjects might be necessary to detect the influence of the *ABCA1* *G(-273)C* polymorphism on MI incidence.

In summary, the present study provides the first evidence that the common *ABCA1* *G(-273)C* polymorphism in the promoter region is significantly associated with the level of HDL cholesterol in the Japanese.

Acknowledgements This study was supported by the Program for the Promotion of Fundamental Studies in Health Science of the Organization for Pharmaceutical Safety and Research of Japan. We would also like to thank Dr. Otsaburo Hishikawa, Dr. Katsuyuki Kawanishi, and Mr. Shigeru Kobayashi for their continuous support of our population survey in Suita City. We also thank the members of the Satsuki-Junyukai. Finally, we express our gratitude to Dr. Soichiro Kitamura, President of the National Cardiovascular Center, and to Dr. Hitonobu Tomoike, Direktor General of the National Cardiovascular Center Hospital, for their support of our study.

References

- Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, Drobnik W, Barlage S, Buchler C, Porsch-Ozcuremez M, Kaminski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G (1999) The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. *Nat Genet* 22:347-351
- Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, et al (1999) Mutations in *ABCI* in Tangier

- disease and familial high-density lipoprotein deficiency. *Nat Genet* 22:336-345
- Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. *JAMA* 256:2835-2838
- Clee SM, Zwinderman AH, Engert JC, Zwarts KY, Molhuizen HOF, Roomp K, Jukema JW, van Wijland M, van Dam M, Hudson TJ, Brooks-Wilson A, Genest J Jr, Kastelein JJ, Hayden MR (2001) Common genetic variation in *ABCA1* is associated with altered lipoprotein levels and a modified risk for coronary artery disease. *Circulation* 103:1198-1205
- Clifton-Bligh P, Nestel PJ, Whyte HM (1972) Tangier disease. Report of a case and studies of lipid metabolism. *N Engl J Med* 286:567-571
- Groenendijk M, Cantor RM, de Bruin TW, Dallinga-Thie GM (2001a) The *apoA1-CIII-AIV* gene cluster. *Atherosclerosis* 157:1-11
- Groenendijk M, Cantor RM, De Bruin TWA, Dallinga-Thie GM (2001b) New genetic variants in the *apoA-I* and *apoC-III* genes and familial combined hyperlipidemia. *J Lipid Res* 42:188-194
- Harada T, Imai Y, Nojiri T, Morita H, Hayashi D, Maemura K, Fukino K, Kawanami D, Nishimura G, Tsushima K, Monzen K, Yamazaki T, Mitsuyama S, Shintani T, Watanabe N, Seto K, Sugiyama T, Nakamura F, Ohno M, Hirata Y, Yamazaki T, Nagai R (2003) A common Ile 823 Met variant of ATP-binding cassette transporter A1 gene (*ABCA1*) alters high-density lipoprotein cholesterol level in Japanese population. *Atherosclerosis* 169:105-112
- Hirakawa M, Tanaka T, Hashimoto Y, Kuroda M, Takagi T, Nakamura Y (2002) JSNP: a database of common gene variations in the Japanese population. *Nucl Acids Res* 30:158-162
- Iida A, Saito S, Sekine A, Kitamura Y, Kondo K, Mishima C, Osawa S, Harigae S, Nakamura Y (2001) High-density single-nucleotide polymorphism (SNP) map of the 150-kb region corresponding to the human ATP-binding cassette transporter A1 (*ABCA1*) gene. *J Hum Genet* 46:522-528
- Katsuya T, Baba S, Ishikawa K, Mannami T, Fu Y, Inamoto N, Asai T, Fukuda M, Higaki J, Ogata J, Ogihara T (2002) Epsilon 4 allele of apolipoprotein E gene associates with lower blood pressure in young Japanese subjects: the Suita Study. *J Hypertens* 20:2017-2021
- Lefevre M, Ginsberg HN, Kris-Etherton PM, Elmer PJ, Stewart PW, Ershow A, Pearson TA, Roheim PS, Ramakrishnan R, Derr J, Gordon DJ, Reed R (1997) *ApoE* genotype does not predict lipid response to changes in dietary saturated fatty acids in a heterogeneous normolipidemic population. The DELTA Research Group. Dietary effects on lipoproteins and thrombogenic activity. *Arterioscler Thromb Vasc Biol* 17:2914-2923
- Lutucuta S, Ballantyne CM, Elghannam H, Gotto AM Jr, Marian AJ (2001) Novel polymorphisms in promoter region of ATP binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy. *Circ Res* 88:969-973
- Mannami T, Konishi M, Baba S, Nishi N, Terao A (1997) Prevalence of asymptomatic carotid atherosclerotic lesions detected by high-resolution ultrasonography and its relation to cardiovascular risk factors in the general population of a Japanese city: the Suita Study. *Stroke* 28:518-525
- Marcil M, Brooks-Wilson A, Clee SM, Roomp K, Zhang LH, Yu L, Collins JA, van Dam M, Molhuizen HO, Loubster O, Oueltte BF, Sensen CW, Fichter K, Mott S, Denis M, Boucher B, Pimstone S, Genest J Jr, Kastelein JJ, Hayden MR (1999) Mutations in the *ABCI* gene in familial HDL deficiency with defective cholesterol efflux. *Lancet* 354:1341-1346
- Porsch-Ozcuremez M, Langmann T, Heimerl S, Borsukova H, Kaminski WE, Drobnik W, Horner C, Schumacher C, Schmitz G (2001) The Zinc finger protein 202 (ZNF202) is a transcriptional repressor of ATP-binding cassette transporter A1 (*ABCA1*) and *ABCG1* gene expression and a modulator of cellular lipid efflux. *J Biol Chem* 276:12427-12433
- Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denefle P, Assmann G (1999) Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. *Nat Genet* 22:352-355
- Sacco RL, Benson RT, Kargman DE, Boden-Albala B, Tuck C, Lin IF, Cheng JF, Paik MC, Shea S, Berglund L (2001) High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. *JAMA* 285:2729-2735
- Shioji K, Kokubo Y, Mannami T, Inamoto N, Morisaki H, Mino Y, Tago N, Yasui N, Iwai N (2004) Association between hypertension and the α -adducin, β 1-adrenoreceptor and G-protein β 3 subunit genes in the Japanese population: the Suita Study. *Hypertens Res* (in press)
- Singaraja RR, Brunham LR, Visscher H, Kastelein JJP, Hayden MR (2003) Efflux and atherosclerosis. The clinical and biochemical impact of variation in the *ABCA1* gene. *Arterioscler Thromb Vasc Biol* 23:1322-1332
- Takagi S, Iwai N, Yamauchi R, Kojima S, Yasuno S, Baba T, Terashima M, Tsutsumi Y, Suzuki S, Morii I, Hanai S, Ono K, Baba S, Tomoike H, Kawamura A, Miyazaki S, Nonogi H, Goto Y (2002) Aldehyde dehydrogenase 2 gene is a risk factor for myocardial infarction in Japanese men. *Hypertens Res* 25:677-681
- Wang N, Tall AR (2003) Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux. *Arterioscler Thromb Vasc Biol* 23:1178-1184
- Wang J, Burnett JR, Near S, Young K, Zinman B, Hanley AJ, Connelly PW, Harris SB, Hegele RA (2000) Common and rare *ABCA1* variants affecting plasma HDL cholesterol. *Arterioscler Thromb Vasc Biol* 20:1983-1989

Lesion Severity and Hypercholesterolemia Determine Long-Term Prognosis of Vasospastic Angina Treated With Calcium Channel Antagonists

Masakazu Yamagishi, MD; Kenichi Ito, MD; Hiroshi Tsutsui, MD; Shunichi Miyazaki, MD; Yoichi Goto, MD; Noritoshi Nagaya, MD; Tetsuya Sumiyoshi, MD*; Kenichi Fukami, MD**; Kazuo Haze, MD†; Masafumi Kitakaze, MD; Hiroshi Nonogi, MD; Hitonobu Tomoike, MD

Although patients with medically treated vasospastic angina have a good outcome, few data exist regarding the role of underlying lesion severity associated with or without hyperlipidemia in the prognosis. Therefore, the aim of the present study was to assess the relationship between the long-term outcome of vasospastic angina and the factors influencing its prognosis. A total of 256 patients (219 men, 37 women; mean age, 54.1±9.2) who had coronary spasm with or without underlying lesions and were being treated with calcium channel antagonists were enrolled and followed for 13.6±3.7 years. Cardiac events consisted of cardiac death and ischemic events, which included acute myocardial infarction and unstable angina. Cox analysis selected coronary artery stenosis (CAS, ≥50%) and risk factors such as age, hypertension, diabetes mellitus, low-density lipoprotein-cholesterol (LDL-C), sex and smoking. There were 19 cases of cardiac death (7.4%) and 58 of ischemic events (22.7%) during the follow-up period. The presence of significant CAS was an independent predictor of event-free survival (hazard ratio (HR)=2.84, 95% confidence interval (CI)=1.79–4.52, $p<0.0001$). In 193 patients without significant CAS, there were 10 cases of cardiac death (5.2%, $p<0.05$) and 34 of ischemic events (17.6%, $p<0.01$). In that group, high LDL-C was the independent predictor of event-free survival (HR=3.89, 95% CI=1.20–12.6, $p=0.02$). Kaplan-Meier survival analysis revealed significantly lower event-free survival in patients with than in those without lesions ($p<0.0001$ by log-rank test). These results demonstrate that the most important factor for long-term prognosis of vasospastic angina treated with calcium channel antagonists is significant CAS. High LDL-C, which might alter the underlying coronary endothelial function and/or accelerate atherosclerotic lesions, could also contribute to the occurrence of cardiac events, particularly in patients without significant CAS. (Circ J 2003; 67: 1029–1035)

Key Words: Calcium channel antagonist; Coronary artery disease; Long-term prognosis; Vasospasm

Coronary spasm provokes the myocardial ischemia associated with angina pectoris, acute myocardial infarction and sudden death.^{1,2} Calcium channel antagonists, nitrates or a combination of both drugs have been used effectively to prevent coronary spasm.^{3–6} Indeed, the overall cardiac mortality is relatively low and the prognosis seems to be good for medically treated patients with coronary spasm.^{7–9} Coronary spasm frequently occurs in minimally narrowed coronary segments,^{10,11} suggesting a pathophysiologic correlation between coronary spasm and atherosclerosis, which has been demonstrated in an experimental animal model.¹² Several studies have examined the relationship between the clinical characteristics and prognosis of this type of angina, and demonstrated that preexist-

ing atherosclerosis could be an important risk factor for cardiac death and myocardial infarction during the relatively early phase.^{5–9} However, there is little information regarding the long-term prognosis of medically treated coronary spasm with or without atherosclerotic risks, such as underlying coronary artery stenosis (CAS) and intrinsic hyperlipidemia. Such data should be important for not only preventing vasospasm, but also preventing the development of atherosclerosis. The purpose of this study was, first, to determine the event-free survival rate in patients with angiographically documented coronary spasm, and second, to identify the clinical predictors of cardiac events, particularly in patients with and without significant CAS.

Methods

Patient Population

Of 2,740 patients who underwent diagnostic coronary angiography for suspected ischemic heart disease between 1977 and 1987, 284 consecutive patients with coronary spasm were enrolled and followed. During the follow-up, 21 patients went missing. Patient enrollment was completed in 1987 when 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, which might have altered the long-term prognosis,¹³ was not generally available. Therefore, no patient had been given HMG-CoA reductase

(Received April 30, 2003; revised manuscript received September 24, 2003; accepted September 26, 2003)

Division of Cardiovascular Medicine, National Cardiovascular Center, Suita, *Division of Cardiology, Sakakibara Heart Institute, Tokyo, **Division of Cardiology, Iwate Medical College, Morioka and †Division of Cardiology, Osaka City General Hospital Medical Center, Osaka, Japan

A part of this work was presented at American Heart Association Scientific Sessions in Anaheim, 2001.

Mailing address: Masakazu Yamagishi, MD, PhD, FACC, Division of Cardiovascular Medicine, National Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan. E-mail: myamagi@hsp.nccv.go.jp

Table 1 Baseline Clinical and Angiographic Characteristics

	Total (n=256)	Without CAS (n=193)	With CAS (n=63)	p value
Age (years)	54.1±9.2	54.4±8.0	55.0±10.3	NS
Male sex (%)	219 (85.5)	163 (84.5)	56 (88.9)	NS
Coronary risk factors				
Hypertension (%)	115 (44.9)	91 (47.2)	24 (38.0)	NS
High LDL-C (%)	61 (23.8)	39 (20.2)	22 (34.9)	NS
Diabetes mellitus (%)	7 (2.7)	3 (1.6)	4 (6.3)	NS
Smoking (%)	174 (66.8)	129 (66.8)	45 (71.4)	NS
Arrhythmia during angina (%)	10 (3.9)	10 (5.2)	0 (0)	NS
Multivessel spasm (%)	18 (7.0)	17 (8.8)	1 (1.6)	NS

CAS, coronary artery stenosis; LDL-C, low-density lipoprotein-cholesterol.

Table 2 Incidence of Cardiac Events During Follow-up Period

Cardiac event	Total (n=256)	Without CAS (n=193)	With CAS (n=63)	p value
Cardiac death (%)	19 (7.4)	10 (5.2)	9 (14.3)	0.017
Sudden death (%)	8 (3.1)	3 (1.6)	5 (7.9)	0.024
Myocardial infarction (%)	3 (1.1)	2 (1.0)	1 (1.6)	NS
Heart failure (%)	5 (2.0)	4 (2.1)	1 (1.6)	NS
Others (%)	3 (1.2)	1 (0.5)	2 (3.2)	NS
Ischemic event (%)	58 (22.7)	34 (17.6)	24 (38.1)	<0.01
Nonfatal myocardial infarction (%)	15 (5.9)	8 (4.1)	7 (11.1)	0.041
Unstable angina (%)	29 (11.3)	21 (10.9)	8 (12.7)	NS
PTCA (%)	12 (4.7)	5 (2.6)	7 (11.1)	0.011
CABG (%)	2 (0.8)	0 (0)	2 (3.2)	NS
Time of event from registration (years)	4.9±4.7	4.6±4.3	5.3±5.3	NS

CABG, coronary artery bypass grafting; CAS, coronary artery stenosis; PTCA, percutaneous transluminal coronary angioplasty.

inhibitor at the time follow-up began, but 7 patients were unexpectedly given this drug during the follow-up period, particularly after 1990. Therefore, these 28 patients were excluded, and a total of 256 patients were analyzed in this study. There were 219 men and 37 women aged 54.1±9.2 years. All the patients had chest pain at rest and/or on exertion. ECG changes such as ST elevation or depression during chest pain attacks were demonstrated in 154 patients.

Cardiac Catheterization Procedures

Written informed consent was obtained from all patients for cardiac catheterization and the provocation of coronary spasm. All patients were fasted and received 3,000–5,000U heparin intravenously before the procedure. Calcium channel antagonists, nitrates, β -blockers and other anti-anginal drugs were discontinued at least 9h before procedures, because these drugs could alter the basal coronary tone associated with the occurrence of spasm.

After control coronary angiography, the provocative tests were performed. We initially used intravenous ergonovine to induce spasm,¹⁴ but since 1986, the intracoronary ergonovine test has been used for safety reasons.¹⁵ When coronary spasm was not provoked, ergonovine maleate was administered until the total dose reached 0.4mg in the intravenous test, or 0.04mg in the intracoronary test. Under these conditions, the standard 12-lead ECG was continuously monitored to record ST change (≥ 0.1 mV) and associated arrhythmias. When chest pain or significant ST-segment changes were observed, selective coronary angiography was immediately performed. Coronary spasm was considered positive when there was luminal narrowing $\geq 75\%$; however, diffuse spasm $\geq 75\%$ without signs of myocardial ischemia was not considered positive, because

it is difficult to differentiate real spasm from a pharmacological reaction!¹⁶ Multi-vessel spasm was defined as vasospasm in more than one major coronary artery.

After provocation, 0.25–0.5 mg (0.5 mg/ml) nitroglycerin was given to obtain maximal coronary dilation, and coronary angiography was again performed in multiple projections to evaluate the extent and severity of CAS. Left ventriculography was performed to calculate the left ventricular ejection fraction by the area-length method. Coronary angiography and left ventriculography were evaluated by at least 2 angiographers who were independent of each other. Significant CAS was defined as lumen stenosis $\geq 50\%$. In the case of repeated angiography, progression of lesion severity was defined as an increase of $\geq 20\%$ in a preexisting stenosis of $\geq 50\%$, and an increase of $\geq 30\%$ in a stenosis $< 50\%$, or any increase in lesion severity that resulted in total coronary occlusion. New stenoses were defined as stenoses $\geq 20\%$ that developed at a site that was previously angiographically normal!¹⁷

Assessment of Coronary Risk Factors

The coronary risk factors at baseline were hypertension, diabetes mellitus, high low-density lipoprotein-cholesterol (LDL-C) and history of smoking. Blood sugar, total cholesterol, LDL-C, high-density lipoprotein-cholesterol, and triglycerides were measured on the morning of angiography while the patient was still in a fasting state. In patients who could be followed up for more than 6 months, these variables were re-examined as frequently as possible during the follow-up period. In patients in whom LDL-C had not been measured and the triglyceride concentration was < 300 mg/dl, the LDL-C concentration was calculated using the following equation: LDL-C=(total cholesterol–




Fig 1. Kaplan-Meier analysis of overall mortality and event-free survival rate for entire patient group. Vertical and horizontal axes represent % survival rate and time from registration, respectively.

HDL-C-1/5 triglycerides). Hypertension was defined as systolic blood pressure >140mmHg, diabetes mellitus was defined as fasting glucose >140mg/dl, and high LDL-C was defined as serum LDL-C concentration >140mg/dl. A smoking history was obtained from all patients: smokers were defined as patients who had smoked more than 20 cigarettes per day for >20 years. We also evaluated the contribution of the patients' sex and age to the prognosis.

Long-Term Follow-up

The cardiac events included cardiac death and ischemic events. Cardiac death consisted of sudden death, which was defined as death within 1h after collapse, and death associated with acute myocardial infarction, heart failure, or other cardiovascular disease. Ischemic events consisted mainly of non-fatal myocardial infarction, unstable angina and the need for percutaneous transluminal angioplasty (PTCA) or coronary artery bypass surgery (CABG). Unstable angina was defined as worsening of chest symptoms¹⁸ and except for emergency procedures the indication for PTCA and CABG was considered by at least 2 cardiologists independent of this study.

Myocardial infarction was diagnosed on the basis of the development of a new Q wave in the ECG and elevation of serum concentrations of cardiac enzymes. Unstable angina was defined as repeated anginal attacks at rest. Non-fatal myocardial infarction was defined as survival of the patient who could then be discharged from hospital. In this study, if a patient died of cardiac death and had suffered an ischemic event before death, the cardiac event was not defined as cardiac death, but as an ischemic event. Accordingly, a cardiac event in this study meant the first cardiac event that occurred during follow-up.

All patients were given at least either dihydropyridine or diltiazem hydrochloride. Drug therapy was started immediately after angiographic diagnosis and continued by the individual physicians until the end-point. The end-points of follow-up were the first cardiac event and non-cardiac death without a cardiac event. The follow-up period of each patient was calculated from the date of the initial diagnostic angiography. Those who did not visit for follow-up examination and checking the status of medical compliance were

Table 3 Predictors of Cardiac Events in All Patients During Follow-up Period

	Hazard ratio	95% CI	p value
CAS	2.84	1.79-4.52	<0.0001
High LDL-C	2.21	0.79-6.21	0.079
Diabetes mellitus	1.72	0.94-3.16	0.16
Hypertension	1.21	0.71-2.00	0.45
Sex	1.18	0.59-2.37	0.65
Age	0.99	0.97-1.03	0.89
Smoking	0.99	0.58-1.68	0.96

CAS, coronary artery stenosis; CI, confidence interval; LDL-C, low-density lipoprotein-cholesterol.

followed by telephone interviews with the patient or the family, from whom the status of smoking was carefully elicited. When anginal attacks became frequent or were not relieved by medical treatment, the patient was admitted and coronary angiography was performed again to determine alternative methods of management.

Statistical Analysis

All values are expressed as mean ± SD. Continuous variables were compared by unpaired Students' t-test. Categorical variables were compared by chi-square test (with Fisher's exact test, as appropriate for smaller sample size). Multivariate analysis with Cox proportional-hazards regression analysis was used to assess the independent significance of prognostic factors for cardiac events. Event-free survival rate was calculated using the Kaplan-Meier method, and differences between survival curves were assessed by the log-rank test.¹⁹ Values of p<0.05 were considered significant. Analyses were performed using StatView 4.5 statistical software (Abacus Concepts, Berkeley, CA, USA).

Results

Baseline Data Collection (Table 1)

Coronary spasm was angiographically demonstrated during spontaneous angina in 40 patients and in 216 patients by provocation tests. Spasm in more than one




Fig2. Kaplan-Meier analysis of overall mortality and event-free survival in patients without significant coronary artery stenosis. Vertical and horizontal axes represent % survival rate and time from registration, respectively.

Table 4 Predictors of Cardiac Events in Patients Without Significant CAS During Follow-up Period

	Hazard ratio	95% CI	p value
High LDL-C	3.89	1.20–12.6	0.02
Sex	1.51	0.64–3.59	0.35
Smoking	1.14	0.57–2.28	0.71
Age	0.99	0.95–1.03	0.51
Hypertension	0.95	0.50–1.82	0.87
Diabetes mellitus	0.97	0.13–7.41	0.98

CAS, coronary artery stenosis; CI, confidence interval; LDL-C, low-density lipoprotein-cholesterol.

major coronary artery was demonstrated in 18 patients. Of the 256 patients, 63 had significant CAS; 53 with single-vessel disease, 8 with double-vessel disease, and 2 with triple-vessel disease. Among the remaining 193 patients who did not have significant CAS, 99 exhibited normal coronary angiography after nitroglycerin administration.

ECG during anginal attacks showed ST elevation in 123 patients, depression in 51 patients and no significant ST change in 82 patients. Ventricular tachycardia was recorded in 6 patients, and second- or third-degree atrioventricular block in 4 patients during provoked coronary spasm. Left ventriculography was normal in 200 patients; segmental wall motion abnormalities were observed in 31 patients. Left ventriculography was not performed in 25 patients because previous echocardiography had shown normal wall motion and cardiac systolic function. Ninety-nine patients were treated with a calcium channel antagonist such as dihydropyridine (30–60 mg/day) or diltiazem hydrochloride (90–120 mg/day), and 157 patients with a combination of calcium channel antagonist and nitrate (40–80 mg/day). In addition to these medications, β -blockers were used in 9 patients. The dose of each drug was calculated to prevent the occurrence of angina during daily activities.

Incidence of Cardiac Events During Follow-up (Table 2)

The mean duration of follow-up was 13.6 ± 3.7 years (range 0.3–20 years). The first cardiac event occurred at 4.9 ± 4.7 years from registration. Of the 46 patients who

died during follow-up, 19 died of cardiac death (8 sudden death, 3 myocardial infarction, 5 unexpected heart failure, 3 unknown cause). The other 27 patients died from non-cardiac causes. Ischemic events occurred in 58 patients (non-fatal acute myocardial infarction in 15, unstable angina in 29, PTCA in 12, CABG in 2). The coronary lesions causing the ischemic events were confirmed to coincide with the previous sites of vasospasm in 30 patients and could not be confirmed in the remaining 28 patients.

The overall survival rate was 99.2% at 1 year, 98.0% at 5 years, 93.5% at 10 years and 85.6% at 20 years. Under these conditions, the event-free survival rate was 92.2%, 81.2%, 74.7%, and 62.6%, respectively (Fig 1). When all of the 7 variables were analyzed, the presence of CAS was shown to be an independent predictor of cardiac events (hazard ratio (HR)=2.84, 95% confidence interval (CI)=1.79–4.52, $p < 0.0001$). There was no difference in survival rate between the patients with CAS in the left coronary and right coronary arteries. High LDL-C and diabetes mellitus had relatively high hazard ratios (2.21 and 1.72, respectively) without statistical significance. Other factors were not significant predictors of cardiac events (Table 3).

In patients without CAS, Kaplan-Meier survival analysis revealed an event-free survival rate of 85.5% at 5 years, 79.6% at 10 years, 76.7% at 15 years and 74.6% at 20 years (Fig 2). Under these conditions, high LDL-C was the only independent predictor of event-free survival (HR=3.89, 95% CI=1.20–12.6, $p=0.02$, Table 4). As for the relationship between ST deviation and occurrence of cardiac events, cardiac events occurred in 56 of 174 patients (32.2%) with ST deviation, elevation or depression, during vasospasm and in 21 of 82 patients (25.6%, NS) without ST deviation. In 99 patients with normal angiography after nitroglycerin, the incidence of cardiac events and the event-free survival rate were not different from those of the remaining 94 patients with minimal and not significant lesion ($p=0.074$).

Association Between CAS and Cardiac Events

Although there were no differences in the baseline clinical characteristics between patients with and without CAS




Fig 3. Comparison of event-free survival curves between patients with and without significant coronary artery stenosis (CAS). Vertical and horizontal axes represent % survival rate and time from registration, respectively.

(Table 1), the overall rate of cardiac events was significantly lower in patients without CAS (22.8%) than in those with CAS (52.4%, $p < 0.01$). As for cardiac deaths, 9 of 63 patients with CAS died and only 10 of 193 patients without CAS, yielding a significant difference in cardiac mortality between patients with and without CAS ($p = 0.017$). Also, there was a significant difference in the incidence of sudden death between these subgroups ($p = 0.024$).

Eight of 15 patients with non-fatal myocardial infarction did not have CAS whereas the remaining 7 patients did. Thus, the incidence of non-fatal myocardial infarction in patients without CAS was significantly lower than that in patients with CAS ($p = 0.041$). However, there was no significant difference in the time interval between registration and the first cardiac events in patients without (4.6 ± 4.3 years) and with (5.3 ± 5.3 years) CAS. There was a marked difference in the event-free survival rate between the subgroups with and without CAS ($p < 0.0001$, Fig 3).

Coronary angiography was repeated in 45 of the 256 patients. Progression of coronary atherosclerosis was observed in 10 patients with CAS (45.5%) and in 13 patients without CAS (56.5%, NS). It was interesting that progression of coronary atherosclerosis was more frequently observed at previous sites of spasm (17 patients or 37.8%) than at non-spastic sites (7 patients or 15.5%, $p = 0.016$).

Discussion

Prognostic Value of CAS and High LDL-C

One of the important findings of the present study is that the presence of significant CAS was an independent predictor of event-free survival, as well as the simple survival, in patients with vasospastic angina treated with calcium channel antagonists. The local effect of more complete occlusion during coronary spasm may predispose to malignant arrhythmia or severe myocardial ischemia, although there was no difference in the incidence of cardiac events, including sudden death, in patients with and without ST deviation that may represent the severity of transient myocardial ischemia. Treatment with calcium channel antagonists could reduce this transient ischemia in both patients with and without significant CAS.

Coronary spasm is a possible mechanism for the progression of atherosclerosis.^{17,20,21} Indeed, in the present study repeated coronary angiography revealed that approximately 40% of patients had progression of coronary atherosclerosis at the sites of previously demonstrated vasospasm. We speculate that coronary spasm accelerates the progression of atherosclerosis, resulting in sudden death and other cardiac events. Under these conditions, elevation of the LDL-C concentration might play an important role in aggravating atherosclerosis through the disintegration of endothelial function.²² However, high LDL-C was second to CAS in terms of hazard ratio in all the present patients. It is possible that a relatively close relation of high LDL-C to significant CAS might make it difficult to differentiate LDL-C as an independent factor in the presence of CAS. Actually, this was shown to be the most important independent factor for cardiac events in patients without CAS. Based on an animal model, an important early step in the development of atherosclerotic lesions is endothelial dysfunction associated with high cholesterol, leading to abnormal vessel tonus characterized by paradoxical constriction to physiologic and pathologic stimuli.²³ Vasospasm may be an extreme of this phenomenon and related to lesion development. From this point of view, it is interesting to speculate that high LDL-C may be related to impairment of coronary endothelial dysfunction²⁴ although recent work does not support this hypothesis.²⁵

Previous studies suggest that the occurrence of coronary spasm is independent of plasma cholesterol concentrations; in the present study, two-thirds of the patients had normal cholesterol levels. However, under treatment with calcium channel antagonists, which effectively prevent spasm, conventional risk factors such as hypercholesterolemia might be important for the development of atherosclerotic lesions associated with cardiac events. Also it was unclear in the previous studies whether or not the LDL-C concentration was high, even though the total cholesterol concentration was within normal range.

The finding that the incidence of sudden death was lower than in previous studies may be explained by the small number of patients with life-threatening arrhythmias in the present patient group; Millar et al reported that nearly 80%

of patients who died from sudden death had a history of ventricular tachyarrhythmias²⁶ Even so, 8 patients died suddenly during the follow-up period. It is unclear whether the presence of CAS is a major determinant of sudden death, because sudden death also occurred frequently in patients without CAS²⁷ Although a previous study suggested that spasm in multiple vessels could be an important determinant of prognosis,²⁸ the present study could not confirm this finding because of the small number of patients with multi-vessel spasm. One of the reasons why there were relatively few instances of multi-vessel spasm was the different way of provoking spasm. Selective intracoronary injection of ergonovine might not have induced multi-vessel spasm in some patients in the present study.

Prognostic Value of Other Risk Factors

Except for high LDL-C, there was no statistically significant difference between the other coronary risk factors and cardiac events, although smoking is considered to be one of the major risk factors for the occurrence of vasospastic angina²⁹ The patients with a history of smoking were carefully questioned about whether they had discontinued smoking during the follow-up period, but it is difficult to confirm the actual status of smoking just by questionnaires at the out-patient clinic. Discontinuation or, at least, a reduction in smoking might result in statistical insignificance of the history of smoking as a risk factor for cardiac events and sudden death.

Coronary spasm without CAS has a fairly good long-term clinical outcome, but even so, high LDL-C was an independent prognostic factor in this subgroup. This suggests that for patients with coronary spasm, manipulation of the therapeutic regimen to prevent not only the occurrence of vasospasm, but also the progression of atherosclerosis should be considered. Calcium channel antagonists such as nifedipine or nicardipine do not reduce cardiac events^{30,31} and therefore, a combination with other agents, such as an HMG-CoA reductase inhibitor, that may stabilize the atherosclerotic plaque would further reduce cardiac events in vasospastic angina,³ although the present study excluded patients in whom HMG-CoA reductase inhibitors were given.

The finding that other traditional risk factors were not significant for long-term prognosis can be explained by the specific situation of vasospastic angina. Indeed, previous studies demonstrated that coronary spasm could occur in the absence of hypertension and diabetes mellitus²⁹ Magnesium deficiency, which was not determined in the present study, might be another risk factor for prognosis of coronary spasm, because 50% of patients with recent myocardial infarction have been shown to have coronary spasm associated with it³²

Study Limitations

We previously reported that even in the absence of angiographic coronary disease, atherosclerosis can be demonstrated by intravascular ultrasound at the sites of spasm.^{33,34} Therefore, we could not precisely evaluate the progression or regression of coronary disease in all patients. Prospective follow-up of patients using ultrasound may resolve this problem. Whether patients consistently complied with medication during the follow-up period is important in considering the long-term prognosis. However, the mid-term prognosis of the present study was similar to those of others,^{8,9} which suggests that there was accepta-

ble drug compliance during the follow-up period. The use of different kinds of calcium channel antagonists for treatment may have had a small effect on the long-term prognosis, although dihydropyridines and diltiazem have a similar effect on coronary spasm in the relatively acute phase.³⁻⁶

Although it is clinically interesting to consider the relationship between the frequency of anginal attacks and long-term prognosis, we could not determine the significance, because of difficulty in quantitatively estimating the frequency. For the same reason, it was also difficult to correlate the presence of CAS with anginal frequency.

To further understand the role of high LDL-C in the long-term prognosis of vasospastic angina, the medical regimen of HMG-CoA reductase inhibitors in addition to calcium channel antagonists should be challenged. It is also necessary to compare the long-term prognosis between CAS patients with and without spasm. However, practically, it is difficult to enroll stable patients without coronary spasm, because PTCA or CABG rather than medical treatment is now the primary treatment.³⁵

Finally, the present study dealt only with Japanese patients with coronary spasm. However, despite the racial difference in coronary vasomotor reactivity,³⁶ the clinical outcome of the present patients is similar to the results of studies in Europe and North America. Therefore, the present data provide important information on the long-term prognosis of medically treated coronary spasm patients with or without CAS.

Acknowledgments

We thank Mr Nobuo Shirahashi, MS, for his assistance with the statistical analysis.

This work was supported in part by grants from the Osaka Heart Club, Osaka (to M.Y.), from Daiwa Securities Healthcare Foundation, Tokyo (to M.Y.), and by grants from the Ministry of Health, Welfare and Labor of Japan, Tokyo (to M.K. and H.T.).

References

- Hillis LD, Braunwald E. Coronary-artery spasm. *N Engl J Med* 1978; 299: 695-702.
- Maseri A, Severi S, Nes MD, L'Abbate A, Chierchia S, Marzilli M, et al. 'Variant' angina: One aspect of a continuous spectrum of vasospastic myocardial ischemia. *Am J Cardiol* 1978; 42: 1019-1035.
- Schroeder JS, Lamb IH, Bristow MR, Ginsburg R, Hung J, McAuley BJ. Prevention of cardiovascular events in variant angina by long-term diltiazem therapy. *J Am Coll Cardiol* 1983; 1: 1507-1511.
- Bott-Silverman C, Heupler FA. Natural history of pure coronary artery spasm in patients treated medically. *J Am Coll Cardiol* 1983; 2: 200-205.
- Waters DD, Miller DD, Szlachcic J, Bouchard A, Methe M, Kreeft J, et al. Factors influencing the long-term prognosis of treated patients with variant angina. *Circulation* 1983; 68: 258-265.
- Walling A, Waters DD, Miller DD, Roy D, Pelletier GB, Theroux P. Long-term prognosis of patients with variant angina. *Circulation* 1987; 76: 990-997.
- Nakamura M, Takeshita A, Nose Y. Clinical characteristics associated with myocardial infarction, arrhythmias, and sudden death in patients with vasospastic angina. *Circulation* 1987; 75: 1110-1116.
- Yasue H, Takizawa A, Nagao M, Nishida S, Horie M, Kubota J, et al. Long-term prognosis for patients with variant angina and influential factors. *Circulation* 1988; 78: 1-9.
- Shimokawa H, Nagasawa K, Irie T, Egashira S, Egashira K, Sagara T, et al. Clinical characteristics and long-term prognosis of patients with variant angina: A comparative study between western and Japanese populations. *Int J Cardiol* 1988; 18: 331-349.
- Heupler FA. Syndrome of symptomatic coronary arterial spasm with nearly normal coronary angiograms. *Am J Cardiol* 1980; 45: 873-881.
- Mercurio P, Kronzon I, Winer H. Spasm of normal or minimally narrowed coronary artery in the presence of severe fixed stenoses of the remaining vessels: Clinical and angiographic observations.

- Circulation* 1982; 65: 825–830.
12. Shimokawa H, Tomoike H, Nabeyama S, Yamamoto H, Ishii Y, Tanaka K, et al. Coronary artery spasm induced in miniature swine: Angiographic evidence and relation to coronary atherosclerosis. *Am Heart J* 1985; 110: 300–310.
 13. Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, et al. Effect of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS). *Circulation* 1995; 91: 2528–2540.
 14. Schroeder JS, Bolen JL, Quint RA, Clark DA, Hayden WG, Higgins CB, et al. Provocation of coronary spasm with ergonovine maleate: New test with results in 57 patients undergoing coronary arteriography. *Am J Cardiol* 1977; 40: 487–491.
 15. Hackett D, Larkin S, Chierchia S, Davies G, Kaski JC, Maseri A. Induction of coronary artery spasm by a direct local action of ergonovine. *Circulation* 1987; 75: 577–582.
 16. Miyao Y, Kugiyama K, Kawano H, Motoyama T, Ogawa H, Yoshimura M, et al. Diffuse intimal thickening of coronary arteries in patients with coronary spastic angina. *J Am Coll Cardiol* 2000; 36: 432–437.
 17. Kaski JC, Tousoulis D, McFadden E, Crea F, Pereira WI, Maseri A. Variant angina pectoris: Role of coronary spasm in the development of fixed coronary obstructions. *Circulation* 1992; 85: 619–626.
 18. Chahine RA. Unstable angina: The problem of definition. *Br Heart J* 1975; 37: 1246–1249.
 19. Glantz SA. How to analyze survival data. In: Primer of biostatistics. New York: McGraw-Hill; 1997; 373–402.
 20. Nobuyoshi M, Tanaka M, Nosaka H, Kimura T, Yokoi H, Hamasaki N, et al. Progression of coronary atherosclerosis: Is coronary spasm related to progression? *J Am Coll Cardiol* 1991; 18: 904–910.
 21. Suzuki H, Kawai S, Aizawa T, Kato K, Sunayama S, Okada R, et al. Histological evaluation of coronary plaque in patients with variant angina: Relationship between vasospasm and neointimal hyperplasia in primary coronary lesions. *J Am Coll Cardiol* 1999; 33: 198–205.
 22. Egashira K, Tomoike H, Yamamoto Y, Yamada A, Hayashi Y, Nakamura M. Histamine-induced coronary spasm in regions of intimal thickening in miniature pigs: Roles of serum cholesterol and spontaneous or induced intimal thickening. *Circulation* 1986; 74: 826–837.
 23. Kuga T, Tagawa H, Tomoike H, Mitsuoka W, Egashira S, Ohara Y, et al. Role of coronary artery spasm in progression of organic coronary stenosis and acute myocardial infarction in a swine model: Importance of mode of onset and duration of coronary artery spasm. *Circulation* 1993; 87: 573–582.
 24. Moriyama Y, Tsunoda R, Harada M, Miyao Y, Yoshimura M, Kugiyama K, et al. Nitric oxide-mediated vasodilatation is decreased in forearm resistance vessels in patients with coronary spastic angina. *Jpn Circ J* 2001; 65: 81–86.
 25. Fukuda Y, Teragawa H, Matsuda K, Yamagata T, Matsuura H, Chayama K. Tetrahydrobiopterin improves coronary endothelial function, but does not prevent coronary spasm in patients with vasospastic angina. *Circ J* 2002; 66: 58–62.
 26. Miller DD, Waters DD, Szlachcic J, Theroux P. Clinical characteristics associated with sudden death in patients with variant angina. *Circulation* 1982; 66: 588–592.
 27. MacAlpin RN. Cardiac arrest and sudden unexpected death in variant angina: Complications of coronary spasm that can occur in the absence of severe organic coronary stenosis. *Am Heart J* 1993; 125: 1011–1017.
 28. Ogawa H, Suefuji H, Takazoe K, Soejima H, Sakamoto T, Miyamoto S, et al. Difference in fibrinolytic activity between multivessel coronary spasm and one-vessel coronary spasm. *Am J Cardiol* 2000; 85: 98–101.
 29. Sugiishi M, Takatsu F. Cigarette smoking is a major risk factor for coronary spasm. *Circulation* 1993; 87: 76–79.
 30. Lichtlen PR, Hugenholz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine: Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). *Lancet* 1990; 335: 1109–1113.
 31. Waters D, Lesperance J, Francetich M, Causey D, Theroux P, Chiang YK, et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. *Circulation* 1990; 82: 1940–1953.
 32. Sueda S, Fukuda H, Watanabe K, Suzuki J, Saeki H, Ohtani T, et al. Magnesium deficiency in patients with recent myocardial infarction and provoked coronary artery spasm. *Jpn Circ J* 2001; 65: 643–648.
 33. Yamagishi M, Miyatake K, Tamai J, Nakatani S, Koyama J, Nissen SE. Intravascular ultrasound detection of atherosclerosis at the site of focal vasospasm in angiographically normal or minimally narrowed coronary segments. *J Am Coll Cardiol* 1994; 23: 352–357.
 34. Saito S, Yamagishi M, Takayama T, Chiku M, Koyama J, Ito K, et al. Plaque morphology at coronary sites with focal spasm in variant angina: Study using intravascular ultrasound. *Circ J* 2003; 67: 1041–1045.
 35. Emond M, Mock MB, Davis KB, Fisher LD, Holmes DR Jr, Chaitman BR, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study Registry. *Circulation* 1994; 90: 2645–2657.
 36. Beltrame JF, Sasayama S, Maseri A. Racial heterogeneity in coronary artery vasomotor reactivity: Differences between Japanese and Caucasian patients. *J Am Coll Cardiol* 1999; 33: 1442–1452.

Association of Genetic Polymorphisms of Sodium-Calcium Exchanger 1 Gene, *NCX1*, with Hypertension in a Japanese General Population

Yoshihiro KOKUBO*¹, Nozomu INAMOTO*¹, Hitonobu TOMOIKE*¹, Kei KAMIDE*², Shin TAKIUCHI*², Yuhei KAWANO*², Chihiro TANAKA*³, Yuki KATANOSAKA*³, Shigeo WAKABAYASHI*³, Munekazu SHIGEKAWA*³, Otosaburo HISHIKAWA*⁴, and Toshiyuki MIYATA*³

The Na⁺/Ca²⁺ exchanger (NCX) is a membrane protein involved in calcium homeostasis, catalyzing the exchange of one Ca²⁺ ion for three Na⁺ ions across the cell membrane. The Na⁺/Ca²⁺ exchange has been suggested to play a role in the pathogenesis of hypertension. Therefore, we examined whether genetic variations in *NCX1* were associated with hypertension. Among 15 polymorphisms identified in 96 hypertensive subjects by sequencing the entire exon and promoter regions of *NCX1*, 7 representative polymorphisms with a minor allele frequency of greater than 4% were genotyped in 1,865 individuals, of whom 787 were hypertensive and 1,072 were normotensive. These subjects were residents of Suita City and were randomly selected as a population for the Suita cohort study. Multivariate logistic regression analysis performed after adjusting for age, body mass index, hyperlipidemia, diabetes mellitus, smoking, and drinking revealed that the -23200T>C and -23181T>C polymorphisms in the 5' upstream region of exon 1c were significantly associated with hypertension in men (-23200T>C: CC vs. TC+TT: odds ratio=0.61; 95% confidence intervals: 0.39 to 0.97; *p*=0.04) and in women (-23181T>C: CC vs. TC+TT: odds ratio=1.45; 95% confidence intervals: 1.04 to 2.02; *p*=0.03), respectively. Thus, our study suggests that *NCX1* is one of the genes related to susceptibility to essential hypertension in the Japanese general population.

(*Hypertens Res* 2004; 27: 697-702)

Key Words: *NCX1*, Na⁺/Ca²⁺ exchanger, gene variants, hypertension

Introduction

The Na⁺/Ca²⁺ exchanger (NCX) is an important membrane protein involved in calcium homeostasis in various cell types and catalyzes the electrogenic exchange of one Ca²⁺ ion for three Na⁺ ions across the plasma membrane (1-3). The Na⁺/

Ca²⁺ exchange has been well demonstrated to play a role in the pathogenesis of hypertension. Blaustein *et al.* suggested that excessive Na⁺ retention may secrete an ouabain-like substance that increases the cytosolic Na⁺ concentration by inhibiting the plasmalemmal Na⁺-pump, which increases the cytosolic Ca²⁺ concentration ([Ca²⁺]_i) by reducing Ca²⁺-extrusion via Na⁺/Ca²⁺ exchange (4-6). The increase in arteri-

From the *¹Division of Preventive Cardiology, *²Division of Hypertension and Nephrology, and *³Research Institute, National Cardiovascular Center, Suita, Japan, and **Suita City Medical Association, Suita, Japan.

This study was supported by the Program for Promotion of Fundamental Studies in Health Science of the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan MPI-3.

Address for Reprints: Yoshihiro Kokubo, M.D., Ph.D., Division of Preventive Cardiology, National Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita 565-8565, Japan. E-mail: ykokubo@hsp.ncvc.go.jp

Received March 2, 2004; Accepted in revised form June 4, 2004.

Table 1. Basic Characteristics of Subjects in Suita, a Japanese Urban Population, 2002

	Men (n=858)	Women (n=1,007)
Age (year)	66.3±11.1*	63.3±11.0*
Systolic blood pressure (mmHg)	131.9±19.5*	128.0±19.6*
Diastolic blood pressure (mmHg)	79.7±10.7*	76.6±10.7*
Body mass index (kg/m ²)	23.3±3.0*	22.3±3.2*
Total cholesterol (mmol/l)	5.10±0.78	5.57±0.79*
HDL-cholesterol (mmol/l)	1.42±0.36	1.67±0.40*
Current smokers (%)	30.1 [†]	6.3 [†]
Current drinkers (%)	67.0 [†]	29.3 [†]
Present illness (%)		
Hypertension	47.4 [†]	38.2
Hyperlipidemia	27.4	55.2 [†]
Diabetes mellitus	12.6 [†]	5.2

Values are mean±SD or percentage. Hypertension indicates systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥90mmHg or antihypertensive medication; hyperlipidemia, total cholesterol ≥5.68 mmol/l (220mg/dl) or antihyperlipidemia medication; diabetes, fasting plasma glucose ≥7.0 mmol/l (126 mg/dl) or non-fasting plasma glucose ≥11.1 mmol/l (200 mg/dl) or HbA1c ≥6.5% or antidiabetic medication. * $p < 0.05$ between women and men by Student's *t*-test. [†] $p < 0.05$ between women and men by χ^2 test. HDL, high-density lipoprotein.

al tone caused by high [Ca²⁺]_i would thus result in an elevation of blood pressure. Indeed, several previous studies have reported that Na⁺/Ca²⁺ exchange activity was altered in the renal arterioles or arterial smooth muscle of spontaneous or salt-sensitive hypertensive rats (7–11). However, it is unknown whether such a mechanism relates to the occurrence of essential hypertension.

Of three isoforms (NCX1–3) derived from different genes, NCX1 is predominantly expressed in the heart, neurons and renal tubules, but is expressed at lower levels in other tissues, including the smooth muscle, skeletal muscle, lung and spleen (1–3). The *NCX1* gene (*SLC8A1*) is located on human chromosome 2p22.1 and includes 12 exons (12). There are at least 12 splice variants generated in different combinations from six exons in a tissue-specific manner (13). In addition, five exons encode 5'-untranslated sequences that are under the control of three tissue-specific promoters (14–17).

This study was undertaken to identify genetic variations in *NCX1* in a group of hypertensive subjects, and to examine the association of these variations with the presence of hypertension in a general population. In contrast to other association studies, which often focus on a limited number of polymorphisms in a gene, our study evaluated the full array of coding- and promoter-sequence polymorphisms in *NCX1*.

Methods

Subjects of the Suita Population Study

The subjects of the Suita study consisted of 14,200 men and women (30 to 79 years of age), who had been randomly selected from the municipal population registry and stratified

by in consideration of gender and age (stratified in 10-year intervals). They were all invited, by letter, to receive medical and behavioral examinations every 2 years at the Division of Preventive Cardiology, National Cardiovascular Center, Japan. DNA from the leukocytes was collected from participants who visited the National Cardiovascular Center between May 2002 and February 2003. All of the participants were Japanese. Only those who gave written informed consent for genetic analyses were included in this study. The study protocol was approved by the Ethical Review Committee of the National Cardiovascular Center. In this study, the genotypes of 1,865 samples were determined. The characteristics of 1,865 participants (858 men, 1,007 women) are shown in Table 1. Routine blood examinations that included total serum cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride, and glucose levels were performed. A physician or nurse interviewed each patient in regard to smoking and drinking habits and personal history of cardiovascular disease, including angina pectoris, myocardial infarction, and/or stroke.

Blood pressure was measured in a sitting position after at least 10 min of rest. Systolic and diastolic blood pressures (SBP/DBP) were taken as the means of two measurements recorded more than 3 min apart by well-trained doctors. Hypertension was defined as SBP of ≥140 mmHg, DBP of ≥90 mmHg, or the current use of antihypertensive medication (18). Diabetes mellitus was defined as fasting plasma glucose ≥7.0 mmol/l (126 mg/dl), non-fasting plasma glucose ≥11.1 mmol/l (200 mg/dl), current use of antidiabetic medication, or HbA1c ≥6.5%. Hyperlipidemia was defined as total cholesterol ≥5.68 mmol/l (220 mg/dl) or current use of antihyperlipidemia medication. Body mass index (BMI)




Fig. 1. Genome structure of human NCX1. The NCX1 gene consists of sixteen exons, five (exons 1a–1e) of which direct tissue-specific transcription and eleven (exons 2–12) of which encode the open reading frame (17). The five tissue-specific transcription exons (exons 1a–1e) and the exons in which the SNPs were identified are depicted. The nucleotide changes and amino acid substitutions are also shown. The A of the ATG of the initiator Met codon is denoted nucleotide +1.

was calculated as weight (in kg) divided by height (in m) squared.

Direct Sequencing for Single Nucleotide Polymorphism (SNP) Discovery and Genotyping of Polymorphisms

For DNA sequencing, 96 patients with essential hypertension were recruited from the Division of Hypertension and Nephrology, National Cardiovascular Center, Japan. The method of direct sequencing was described previously (19). Fifteen polymorphisms were identified by sequencing and 7 representative polymorphisms with a minor allele frequency of greater than 4% were genotyped by the TaqMan-polymerase chain reaction (PCR) system (20). Only those who gave written informed consent for genetic analyses were included in this study. The study protocol was approved by the Ethical Review Committee of the National Cardiovascular Center.

Statistical Analysis

Analysis of variance was used to compare mean values between groups, and if overall significance was demonstrated, the intergroup difference was assessed by means of a general linear model. Frequencies were compared by χ^2 analysis.

Logistic regression analyses were used to examine the association between the genotypes and blood pressure in each sex with consideration for potential confounding risk variables, including age, BMI, present illness (hyperlipidemia and diabetes mellitus), lifestyle (smoking and drinking), and antihypertensive medication. For multivariate risk predictors, the adjusted odds ratios were given with 95% confidence intervals. The relationship between genotype and risk of hypertension was expressed in terms of the odds ratios adjusted for possible confounding effects including age, BMI, present illness (hyperlipidemia and diabetes mellitus), and lifestyle (smoking and drinking). SAS statistical software (release

8.2; SAS Institute, Cary, USA) was used for statistical analyses (21).

Results

Basic Characteristics of Subjects in the Suito Study

The characteristics of the 1,865 participants (858 men, 1,007 women) are summarized in Table 1. Age, SBP, DBP, BMI, percentage of current smokers, percentage of current drinkers, and prevalence of hypertension and diabetes mellitus were significantly higher in men than in women. Total cholesterol, HDL-cholesterol, and percentage of hyperlipidemia were significantly higher in women than in men.

Polymorphisms of NCX1

The NCX1 gene has a complicated genome structure containing five alternative 5' exons producing separate tissue-specific promoters and six exons encoding open reading frames (Fig. 1). We sequenced the entire exon and promoter regions of NCX1 from 96 patients (182 alleles) with hypertension, and identified 15 polymorphisms (Table 2, Fig. 1). We identified two missense mutations, Arg5Gln in exon 2 and Arg703Cys in exon 9, in NCX1 (Table 2). Each of the missense mutations was identified in one out of 96 individuals, indicating that their allele frequencies were rare. Two SNPs, -23200T>C and -23186G>C, were in linkage disequilibrium. Seven representative polymorphisms with a minor allele frequency of greater than 4% were genotyped for the association study.

Susceptible SNPs Related to Hypertension

Seven polymorphisms in NCX1 were genotyped in 1,865 individuals, of whom 787 were hypertensive and 1,072 were normotensive. The primers and probes of the TagMan-PCR system and the genotyping results are summarized in Table

Table 2. List of 15 Polymorphisms and Their Allele Frequencies in the *NCX1* Gene Identified by Direct Sequencing

Allele 1/Allele 2 SNPs	TaqMan typing	Amino acid change	Region	Allele 1 Homo	Hetero	Allele 2 Homo	Total	Allele frequency		Flanking sequence
								Allele 1	Allele 2	
-23846A>C			intron 1d	94	1	0	95	0.995	0.005	tcacactgcctt[a/c]aattcagggact
-23690T>C	typing		intron 1d	62	31	2	95	0.816	0.184	aaattaactta[u/c]agcaaggaaaga
-23449C>A	typing		intron 1d	85	9	1	95	0.942	0.058	catactcacatt[c/a]atgtttgaggag
-23200T>C*	typing		intron 1d	0	9	86	95	0.047	0.953	attccgccccct[u/c]tttgttgcggag
-23186G>C*			intron 1d	0	9	86	95	0.047	0.953	ttgttgcggagg[g/c]aaactgaggttc
-23181T>C	typing		intron 1d	18	57	20	95	0.489	0.511	gcggaggcaaac[u/c]gaggttctctgga
-22729A>C	typing		intron 1c	71	23	1	95	0.868	0.132	taattatgagga[a/c]agtgattattg
-22660delA			intron 1c	94	1	0	95	0.995	0.005	gattgctgcatt[a/-]jggtttttccca
-22387A>C		5' UTR	exon 1b	93	3	0	96	0.984	0.016	ataaaaaaaaa[a/c]tcattgatatat
-22144C>G	typing		intron 1b	84	9	2	95	0.932	0.068	gcgcgcccaac[a/g]gcactgcggggc
14G>A		Arg5Gln	exon 2	95	1	0	96	0.995	0.005	tgtacaacatgc[g/a]gcgattaagctc
303C>T		Ser101Ser	exon 2	95	1	0	96	0.995	0.005	tcggttcatgtc[c/t]tctatagaagtc
252581G>A	typing		intron 4	45	40	11	96	0.677	0.323	tcttctctccc[g/a]tgtctcctact
255089-255090insA			intron 5	94	1	0	95	0.995	0.005	tcaggtgataca[-/a]gtagctctgtga
265364C>T		Arg703Cys	exon 9	95	1	0	96	0.995	0.005	gcagaaatgggg[c/t]gcccatcctgg

The A of the ATG of the initiator Met codon is denoted nucleotide +1. * The apparent linkage disequilibrium ($r^2 \geq 0.5$). *NCX1*, Na⁺/Ca²⁺ exchanger; SNP, single nucleotide polymorphism.

3. Multivariate logistic regression analysis after adjusting for confounding risk variables such as age, BMI, hyperlipidemia, diabetes mellitus, smoking, and drinking, revealed that two polymorphisms, -23200T>C and -23181T>C, in the 5' upstream region of exon 1c were significantly associated with hypertension in men (-23200T>C: CC vs. TC+TT: odds ratio=0.61; 95% confidence interval: 0.39 to 0.97; $p=0.04$) and in women (-23181T>C: CC vs. TC+TT: odds ratio=1.45; 95% confidence interval: 1.04 to 2.02; $p=0.03$), respectively (Table 4). When normotension was defined as SBP ≤ 120 mmHg, DBP ≤ 80 mmHg, and the absence of anti-hypertensive medication, and hypertension was defined as SBP ≥ 160 mmHg, DBP ≥ 100 mmHg, or the current use of antihypertensive medication, -23200T>C polymorphism was significantly associated with hypertension in men (CC vs. TC+TT: odds ratio=0.42; 95% confidence interval: 0.20 to 0.92; $p=0.03$) after adjusting for the confounding factors described above.

Discussion

In this study, we sequenced the exon and promoter regions of *NCX1* and identified 15 polymorphisms. Seven representative polymorphisms were genotyped from 1,865 subjects to examine the association of hypertension with *NCX1*. After adjustment for various confounding factors, we identified that the -23200T>C polymorphism in the 5' upstream region of exon 1c was significantly associated with hypertension in men and the -23181T>C polymorphism in the 5' upstream region of exon 1c was significantly associated with hypertension in women.

The *NCX1* gene has at least 12 splice variants generated in different combinations from six exons in a tissue-specific manner (13). In addition, three exons encode 5'-untranslated sequences that are under the control of three tissue-specific promoters (14-16). Exon 1c is a part of the "heart" specific transcript (17) and its upstream region is not likely a promoter. Therefore, the -23200T>C and -23181T>C polymorphisms present in the upstream region of exon 1c are not likely to be directly involved in transcription of *NCX1*. Rather, these polymorphisms may be in linkage disequilibrium with other polymorphisms in the region that were not examined by sequencing in this study.

In this study, the -23200T>C polymorphism in men and -23181T>C polymorphism in women were identified as SNPs conferring susceptibility for hypertension. It is well known that the greater incidence of hypertension and coronary artery disease in men is, in part, related to gender differences in possible vascular protective effects of the female sex hormones estrogen and progesterone. Furthermore, *NCX1* might be related to salt-sensitive hypertension (22). Since there is a gender difference in salt-sensitivity and plasma renin activity (23, 24), -23200T>C and -23181T>C in *NCX1* may be linked with unidentified causative genetic variations that would be influenced by the female sex hormones and/or salt-sensitivity.

In this study, we identified two missense mutations, Arg5Gln in exon 2 and Arg703Cys in exon 9, in *NCX1*. Arg5 is located within the signal peptide sequence consisting of the first N-terminal 35 amino acids of *NCX1*, which are removed during biosynthesis (1). We expressed a mutant canine *NCX1* with the Arg5Gln substitution in the fibroblastic

Table 3. Genotyping Conditions and Results of NCX1 Polymorphisms in 1,818 Individuals by TaqMan-PCR Method

SNP	Primer	Probe	Genotypes results
-23690T>C	CTCTCCCCACAGGTCATTCTG	Fam-ATTTAACTTATAGCAAGGAA-MGB	(TT/TC/CC)
	GCAGGAATCGTTCTTGCCTAA	Vic-TTAACTTACAGCAAGGAA-MGB	=(1,140/590/88)
-23449C>A	GAATCTGCAATCCCCATGTGAT	Fam-CTCACATTCATGTTTGAG-MGB	(CC/CA/AA)
	AGAACCCTGCTCTAGGCCAAT	Vic-ACTCACATTAATGTTTGAGG-MGB	=(1,542/261/15)
-23200T>C	TTCTGAGGTGCAAGGAGGGTT	Fam-CCCCCTTTTGTGTC-MGB	(TT/TC/CC)
	GGCAGTCACCACGACTGATAGA	Vic-CCCCCTTTTGTGTC-MGB	=(4/196/1,618)
-23181T>C	GGCAGTCACCACGACTGATAGA	Fam-TCCAGGAACCTCAGTTT-MGB	(TT/TC/CC)
	AGGCTATTTCTTCCATTCCGC	Vic-CCAGGAACCTCGGTTT-MGB	=(503/869/446)
-22729A>C	GCCTGGTGCAGTGTTCCTTTA	Fam-ATTATGAGGAAAGTGATTTA-MGB	(AA/AC/CC)
	GCCCTTTCCAAGAGAAGCATTAA	Vic-TATGAGGACAGTGATTTA-MGB	=(1,369/406/43)
-22144C>G	AAAAGAAAAGTTGCAGCGCCT	Fam-CCACAACGCACTGC-MGB	(CC/CG/GG)
	TTTTTCGATTTCTGCGCG	Vic-CACAAGGCACTGCG-MGB	=(1,687/131/0)
252581G>A	AAACAAAGACATAACCAGCGAGAAA	Fam-CTCTCTCCGTGTCTC-MGB	(GG/GA/AA)
	AAATTGCTAAAGCTTCAAAGGCA	Vic-TCTCTCCATGTCTCC-MGB	=(823/798/197)

PCR, polymerase chain reaction; SNP, single nucleotide polymorphism.

Table 4. Odds Ratio of -23200T>C Polymorphism in Men and -23181T>C Polymorphism in Women*

Gender	SNP	OR (95% CI)	p	OR (95% CI)	p	
Men	-23200T>C	CC	1 (reference)	0.04	CC+TC	1 (reference)
		TC+TT	0.61 (0.39-0.97)		TT	—
Women	-23181T>C	CC	1 (reference)	0.03	CC+TC	1 (reference)
		TC+TT	1.45 (1.04-2.02)		TT	1.39 (1.00-1.92)

*Conditional logistic analysis, adjusted for age, body mass index, present illness (hyperlipidemia and diabetes mellitus), and lifestyle (smoking and drinking). SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence intervals.

cell line CCL39, and found that this mutant NCX1 was properly targeted into the plasma membrane and exhibited the normal $\text{Na}^+/\text{Ca}^{2+}$ exchange activity (unpublished observations), consistent with previous reports stating that signal sequence is not essential for functional expression of the NCX1 protein (25, 26). On the other hand, Arg703 is located within the large cytoplasmic loop connecting the transmembrane segments 5 and 6, which are not essential for the functional expression of the NCX1 protein (1). Thus, the two rare mutations identified in this study would not grossly impair the function of NCX1.

In summary, we showed that the SNPs -23200T>C and -23181T>C in NCX1 were associated with hypertension. The pathophysiological functional behaviors of these polymorphisms remain to be clarified. In future studies, it will be necessary to clarify the function of these polymorphisms or to identify the causative polymorphisms that are in linkage disequilibrium with these polymorphisms.

Acknowledgements

We would like to express our highest gratitude to Dr. Soichiro Kitamura, President of the National Cardiovascular Center, for

his support of the Millennium genome project (MPJ-3). We would also like to thank Dr. Katsuyuki Kawanishi, Dr. Toshifumi Mannami, and Mr. Tadashi Fujikawa for their continuous support of our population survey in Suita City. We also thank the members of the Satsuki-Junyukai. We also thank all the staff in the Division of Preventive Cardiology for supporting medical examination and M. Banno, Y. Tokunaga, and C. Imai for their technical assistance. Finally, we are grateful to Dr. Tetsuji Yokoyama for his statistical advice.

References

- Philipson KD, Nicoll DA: Sodium-calcium exchange: a molecular perspective. *Annu Rev Physiol* 2000; **62**: 111-133.
- Shigekawa M, Iwamoto T: Cardiac $\text{Na}^+/\text{Ca}^{2+}$ exchange: molecular and pharmacological aspects. *Circ Res* 2001; **88**: 864-876.
- Blaustein MP, Lederer WJ: Sodium/calcium exchange: its physiological implications. *Physiol Rev* 1999; **79**: 763-854.
- Blaustein MP: Sodium ions, calcium ions, blood pressure regulation, and hypertension: a reassessment and a hypothesis. *Am J Physiol* 1977; **232**: C165-C173.
- Blaustein MP: Physiological effects of endogenous ouabain: control of intracellular Ca^{2+} stores and cell respon-